Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q4 2017 · 10-K
Revenue$193.80M$193.80M+27.8% vs Q4 2016 Net Income$33.95M$33.95Mderived−9.2% vs Q4 2016 EPS Diluted$0.67$0.67−13.0% vs Q4 2016 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
+4.3%
Operating Incomederived$53,092,000+4.3% Operating Cash Flowderived$77,486,000N/M Free Cash Flowderived$65,067,000N/M Margins · derivedGross margin27.4%−6.2 pt vs Q4 2016
Operating margin27.4%−6.2 pt vs Q4 2016
Net margin17.5%−7.1 pt vs Q4 2016
ended Dec 31, 2017 · filed Feb 23, 2018 · 54 d after period end